ClinicalTrials.gg
RecruitingNCT05743413Updated Jun 22, 2023

Improving the Quality of Life of Stroke Patients Using the Armeo Spring Device

An interventional study of Armeo Spring physiotherapy and Standard physiotherapy in Ischemic Stroke, sponsored by University Hospital Ostrava. Recruiting at 1 site in Czechia. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2023-06-22.

Sponsored by University Hospital Ostrava · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Aug 2023, 3 years 2 months ago, but the record still lists the study as recruiting.
  • Registered 3 months after the study started (first participant enrolled Nov 2022, registered Feb 2023).
  • Started Nov 2022; still recruiting 4 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
10
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 29 studies in Ischemic Stroke with a site in Czechia — 8 open to participants now, 10 under way, 1 of them phase 3. Ischemic Stroke · Czechia.

Planned enrollment
21st of 21
10 · median 532
Started
2022
with 1 other
No phase
5 of 29
3 open now
Registered
25th of 29
by date
Lead sponsor
4 of 29
University Hospital Ostrava

Among the 29 studies in Ischemic Stroke with a site in Czechia, this one is the 21st largest by planned enrollment of the 21 interventional ones that give a count, is one of 2 that started in 2022, is one of 5 with no phase, and was the 25th registered.

Ischemic Stroke

2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.

Browse Ischemic Stroke studies →

Open to participants now

8 of the 29 studies in Ischemic Stroke with a site in Czechia are open now. Recruiting first, the newest first:

2 more — sign in →

All 8 open studies →

A study can be open while its sites in Czechia have not opened yet or have stopped. Only those recruiting at a site in Czechia →

Who these studies take

Of the 668 Ischemic Stroke studies recruiting now, 403 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies in Ischemic Stroke with a site in Czechia, or all of them as a file.
02

Study summary

The main goal will be to evaluate the effect of improving the quality of movement of the upper limb (using an evaluation exercise in the software of the Armeo Spring device) on the development of the quality of life after stroke using a standardized generic and specific questionnaire.

The secondary outcome will be to evaluate changes in self-sufficiency using a test of daily activities modified by the Frenchay test of daily activities.

Read the detailed description

The research follows on from a pilot study that took place at the Department of Rehabilitation and Sports Medicine, University Hospital Ostrava from 4/2022 to 9/2022. It has a prospective monocentric randomized trial design. Patients will be randomized into parallel groups - intervention and control groups.

A prospective monocentric randomized study lasting 8 months at the Department of Rehabilitation and Sports Medicine, University Hospital Ostrava. The study design is parallel with a test and control arm. Patients will be divided into an intervention (tested) group A with therapy on Armeo Spring and a control group B with conventional therapy, using a random number generator, where odd numbers represent arm A and even numbers represent arm B. A randomization table randomly allocates patients to therapy according to their order of entry into the study.

03

Conditions studied

  • Ischemic Stroke

Browse trials for

Keywords

  • ischemic stroke
  • rehabilitation
  • Armeo Spring therapy
  • quality of life
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • history of stroke
  • age over 18 years
  • Modified Rankin Scale (mRS) of 2-3
  • moderate paresis of the upper extremity (individuals with shoulder/elbow muscle test values in the range of 3-1)
  • cardiovascular stability

Exclusion criteria

Exclusion Criteria:

  • age under 18 years
  • severe cognitive or sensory deficit and non-cooperation
  • severe osteoporosis
  • impaired skin integrity in the trunk and upper limbs
  • cardiovascular instability
  • unstable fractures
  • acute inflammatory diseases
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
10 participants (estimated)

Study arms

  • Experimental
    Armeo Spring

    Study subjects randomized into this group will undergo physiotherapy sessions using the Armeo Spring device.

    Procedure: Armeo Spring physiotherapy

  • Active comparator
    Standard physiotherapy

    Study subjects randomized into this control group will undergo standard physiotherapy sessions.

    Procedure: Standard physiotherapy

Interventions

  • ProcedureArmeo Spring physiotherapy

    Study subjects will undergo physiotherapy sessions using the Armeo Spring device.

  • ProcedureStandard physiotherapy

    Study subjects will undergo standard physiotherapy sessions.

06

What researchers measure

Primary outcomes

  1. Change of upper extremity function - A GOAL

    Exercise A Goal is an assessment exercise that aims to evaluate the accuracy of the patient's gross motor movements. After placing the pointer on the base, the target will appear. The patient must try to catch the target in a perfectly linear motion and then stay exactly in the center of the target for 3 seconds.

    Time frame: 3 weeks

  2. Change of upper extremity function - HPR

    The HPR value (hand path ratio) is used to evaluate the quality of the patient's movement. It is calculated by dividing the length of the path of the patient's hand by the distance between the points to be grasped in the exercises. A perfectly straight movement has an HPR value of 1. An HPR value of 2 means that the path length of the patient's hand was twice as long as the shortest line connecting the points.

    Time frame: 3 weeks

  3. Change of upper extremity function - deviation

    The deviation shows the distance of the pointer to the center point of the target s, so it is the accuracy value on the target. The value describes the patient's ability to meet positional accuracy. A perfect match between the indicator and the resulting target position represents a deviation value of 0. A deviation value of 2 means that the patient missed the target position by 2 cm.

    Time frame: 3 weeks

  4. Change of upper extremity function - variability

    Variability represents the standard deviation of the points on the track from their average coordinates and is therefore a value of accuracy on target. The value describes the patient's ability to maintain a steady position. Maintaining a perfectly stable position has a variability value of 0. A variability of 2 cm means that 68% of the points on the track are within 2 cm.

    Time frame: 3 weeks

  5. Quality of Life - EQ-5D

    These are standardized questionnaires, i.e. providing exact results of measuring the quality of life in various domains of health status. The EQ-5D group of questionnaires is used worldwide and is one of the most widely used scales in healthcare. It has been certified and translated into many languages. Its use is validated by recent meta-analyses. The questionnaires monitor a total of 5 domains of quality of life - mobility, self-care, normal activities, pain, discomfort, anxiety and depression.

    Time frame: 3 weeks

Secondary outcomes

  1. Modified Frenchay Scale (MFS) test

    The Modified Frenchay Scale (MFS) measures active upper limb function in hemiparesis based on a video review of 10 everyday living tasks, each rated on a 10-point visual analogic scale. Six tasks are bimanual and four are unimanual performed with the paretic hand.

    Time frame: 3 weeks

  2. The Barthel Index (BI)

    The Barthel Index (BI) measures the extent to which somebody can function independently and has mobility in their activities of daily living (ADL) i.e. feeding, bathing, grooming, dressing, bowel control, bladder control, toileting, chair transfer, ambulation and stair climbing.

    Time frame: 3 weeks

07

Study locations

1 of 1 sites recruiting
  • University Hospital Ostrava
    Ostrava, Moravian-Silesian Region 70852, Czechia
    Recruiting
    • Jiří Hynčica · Contactjiri.hyncica@fno.cz · 0042059737
    • Šárka Anežka Čechová, MD · Principal investigator
    • Šárka Baníková, MD,MBA · Sub investigator
    • Kamila Slezáková, MD · Sub investigator
    • Tomáš Hudeček, MD · Sub investigator
    • Michal Krajňák, MD · Sub investigator
08

References and documents

Individual participant data

Plan to share: No — There is no plan to make individual participant data available to other researchers. The data may be provided upon request.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2022 (actual). Primary completion is estimated for Aug 2023, 9 months after the start.

Of 576 non-industry interventional studies with no phase under Ischemic Stroke, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 48. This study's planned 9 months is below that.

Counting every sponsor, half of 656 studies reached it within 27 months; a quarter within 14 and three quarters within 48.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 14, 2023
First posted
Feb 24, 2023
StartActual
Nov 1, 2022
Primary completionEst.
Aug 31, 2023
CompletionEst.
Oct 31, 2023
Last update
Jun 22, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 22, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05743413
Collaborators
University of Ostrava
Responsible party
Sponsor
First posted
Feb 24, 2023
Start date
Nov 1, 2022
Primary completion
Aug 31, 2023 (estimated)
Completion
Oct 31, 2023 (estimated)
Last update
Jun 22, 2023

Study contacts

Jiří Hynčica
Contact
jiri.hyncica@fno.cz
0042059737 ext. 2587
Šárka Anežka Čechová, MD
principal investigator · University Hospital Ostrava

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion